|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Investigations |
1 Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230
2 Department of Neuropathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230
3 Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230
 |
Abstract |
|---|
Little is known about the immune performance and interactions of CNS microglia/macrophages in glioma patients. We found that microglia/macrophages were the predominant immune cell infiltrating gliomas (~1% of total cells); others identified were myeloid dendritic cells (DCs), plasmacytoid DCs, and T cells. We isolated and analyzed the immune functions of CD11b/c+CD45+ glioma-infiltrating microglia/macrophages (GIMs) from postoperative tissue specimens of glioma patients. Although GIMs expressed substantial levels of Toll-like receptors (TLRs), they did not appear stimulated to produce pro-inflammatory cytokines (tumor necrosis factor 
, interleukin 1, or interleukin 6), and in vitro, lipopolysaccharides could bind TLR-4 but could not induce GIM-mediated T-cell proliferation. Despite surface major histocompatibility complex class II expression, they lacked expression of the costimulatory molecules CD86, CD80, and CD40 critical for T-cell activation. Ex vivo, we demonstrate a corresponding lack of effector/activated T cells, as glioma-infiltrating CD8+ T cells were phenotypically CD8+CD25-. By contrast, there was a prominent population of regulatory CD4 T cells (CD4+CD25+FOXP3+) infiltrating the tumor. We conclude that while GIMs may have a few intact innate immune functions, their capacity to be stimulated via TLRs, secrete cytokines, upregulate costimulatory molecules, and in turn activate antitumor effector T cells is not sufficient to initiate immune responses. Furthermore, the presence of regulatory T cells may also contribute to the lack of effective immune activation against malignant human gliomas.
Key Words: costimulation, human glioma, macrophages, microglia, regulatory T cells, tumor immunotherapy
This article has been cited by other articles:
|
|
 |
|
  S. F. Hussain, L.-Y. Kong, J. Jordan, C. Conrad, T. Madden, I. Fokt, W. Priebe, and A. B. Heimberger A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients Cancer Res., October 15, 2007; 67(20): 9630 - 9636. [Abstract] [Full Text] [PDF]
|
|
|
|
